SCHEMBL578407

SCHEMBL578407

Fc1cc(OCCOC2CCCCO2)ccc1Br

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
KDM4C Q9H3R0 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
NSD2 O96028 1/20 0.38
NSD3 Q9BZ95 1/20 0.38
CHEK1 O14757 1/20 0.37
MAOB P27338 2/20 0.35
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
PARP10 Q53GL7 1/20 0.33
P2RX3 P56373 1/20 0.33
GPR119 Q8TDV5 1/20 0.32
LSS P48449 1/20 0.32
MCHR1 Q99705 1/20 0.32
IDO1 P14902 1/20 0.32
ALOX5AP P20292 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2198944 0.85 MEN1 (0.49) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL5453573 0.85 MEN1 (0.49) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL7263741 0.81 MEN1 (0.59) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL2017636 0.81 HSD11B1 (0.40) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL5460947 0.80 MEN1 (0.47) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL17624780 0.80 MEN1 (0.55) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL28667185 0.80 KDM4C (0.50) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL22597190 0.79 MEN1 (0.57) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL2198305 0.79 MEN1 (0.54) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL16207956 0.79 PARP10 (0.42) MEN1KMT2AL3MBTL1MAOBPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325708-B2 Adenosine 2 receptor antagonists NEKTAR THERAPEUTICS (US) 2025-06-10 US disclosed
US-20220235056-A1 ADENOSINE 2 RECEPTOR ANTAGONISTS NEKTAR THERAPEUTICS 2022-07-28 US disclosed
WO-2020227156-A1 ADENOSINE 2 RECEPTOR ANTAGONISTS NEKTAR THERAPEUTICS (US) 2020-11-12 WO disclosed
EP-2418203-B1 CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP DAIICHI SANKYO CO LTD (JP) 2013-12-11 EP disclosed
US-8410273-B2 Cyclic compound having substituted phenyl group DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-04-02 US disclosed
US-20120040936-A1 CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-02-16 US disclosed
EP-2418203-A1 CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP Daiichi Sankyo Company, Limited (JP) 2012-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235056-A1 ADENOSINE 2 RECEPTOR ANTAGONISTS ADORA2A, ADORA2B, ADORA3 MEN1 2205/4885KMT2A 754/4885KDM4C 2727/4885
US-20120040936-A1 CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP BMP2, BMP4, BMP6 MEN1 2101/4885KMT2A 2350/4885KDM4C 2332/4885
US-12325708-B2 Adenosine 2 receptor antagonists ADORA2A, ADORA2B, ADORA3 MEN1 2205/4885KMT2A 754/4885KDM4C 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.